

Elvin Kedhi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/923555/publications.pdf>

Version: 2024-02-01

86
papers

3,317
citations

279798

23
h-index

149698

56
g-index

98
all docs

98
docs citations

98
times ranked

3684
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids and crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 4-12.	3.0	34
2	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1-month dual antiplatelet therapy following <sc>PCI</sc>: Analysis from the <sc>Onyx ONE</sc> clear study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 583-592.	1.7	3
3	Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 463-474.	2.2	2
4	Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events in Diabetic Patients: Insights From the COMBINE OCT-FFR Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS121011728.	3.9	12
5	Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1153-1163.	2.9	10
6	Impact of aging on the effects of intracoronary adenosine, peak hyperemia and its duration during fractional flow reserve assessment. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 625-631.	0.7	3
7	Low hemoglobin predicts high platelet reactivity and major cardiovascular ischemic events at long-term follow-up among <sc>ACS</sc> patients receiving dual antiplatelet therapy with ticagrelor. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1309-1316.	1.7	6
8	Impact of the Polymorphism rs5751876 of the Purinergic Receptor ADORA2A on Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 137-145.	2.0	1
9	Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial. <i>Atherosclerosis</i> , 2021, 321, 39-44.	0.8	6
10	Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials. <i>Vascular Pharmacology</i> , 2021, 137, 106828.	2.1	4
11	FINAL TWO-YEAR RESULTS FROM THE RANDOMIZED ONYX ONE TRIAL IN HIGH BLEEDING RISK PATIENTS TREATED WITH 1-MONTH DAPT. <i>Journal of the American College of Cardiology</i> , 2021, 77, 899.	2.8	2
12	Benefits with drug-coated balloon as compared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: a comprehensive meta-analysis of 45 randomized trials. <i>Vascular Pharmacology</i> , 2021, 138, 106859.	2.1	7
13	Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111469.	5.6	3
14	Ticagrelor and prasugrel in acute coronary syndrome: a single-arm crossover platelet reactivity study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 686-692.	1.5	3
15	Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. <i>European Heart Journal</i> , 2021, 42, 4671-4679.	2.2	121
16	El peligro de los metanálisis. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 817-818.	1.2	0
17	Intravascular imaging beyond ischaemia assessment: a possible way for improving risk stratification. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, , .	1.2	1
18	The danger of meta-analyses. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 817-818.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. <i>Atherosclerosis</i> , 2021, 332, 48-54.	0.8	28
20	Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-Dragon-Registry). <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010868.	3.9	9
21	Effects of chronic beta-blocker treatment on admission haemodynamics in STEMI patients treated with primary angioplasty. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 462-468.	1.0	1
22	Impact of elevated HbA1c on long-term mortality in patients presenting with acute myocardial infarction in daily clinical practice: insights from a "real world" prospective registry of the Zwolle Myocardial Infarction Study Group. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 616-625.	1.0	14
23	Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 706-710.	1.7	2
24	Polymer-Free vs. Polymer-Coated Drug-Eluting Stents for the Treatment of Coronary Artery Disease: A Meta-Analysis of 16 Randomized Trials. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 745-753.	0.8	10
25	Benefits of short-term or prolonged as compared to standard 1-year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 337-354.	2.1	7
26	Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 813-824.	1.7	5
27	Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention. <i>Current Atherosclerosis Reports</i> , 2020, 22, 76.	4.8	4
28	PROGNOSTIC IMPACT OF AGE WITH SHORT-TERM VS. 12 MONTHS DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: A SUB-ANALYSIS OF THE REDUCE TRIAL. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1229.	2.8	0
29	Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor. <i>Vascular Pharmacology</i> , 2020, 132, 106765.	2.1	16
30	Duration of dual antiplatelet therapy after myocardial infarction: Insights from a pooled database of the SMART-DATE and DAPT-STEMI trials. <i>Atherosclerosis</i> , 2020, 315, 55-61.	0.8	4
31	Comparison of overexpansion capabilities and thrombogenicity at the side branch ostia after implantation of four different drug eluting stents. <i>Scientific Reports</i> , 2020, 10, 20791.	3.3	9
32	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009565.	3.9	49
33	TCT CONNECT-281 Clinical Outcomes of Optical Coherence Tomography Detected High-Risk Versus Low-Risk Coronary Atherosclerotic Lesions in Medically Treated Fractional Flow Reserve Negative Lesions in Diabetes Mellitus Patients: The COMBINE Trial. <i>Journal of the American College of Cardiology</i> , 2020, 76, B122.	2.8	0
34	Short-term healing response after implantation of the thin-strut, fast-releasing sirolimus-eluting biodegradable polymer-coated Alex Plus stent: optical coherence tomography study. <i>Postępy W Kardiologii Interwencyjnej</i> , 2020, 16, 187-191.	0.2	1
35	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2321-2330.	2.8	154
36	Impact of gender on immature platelet count and its relationship with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 511-521.	2.1	4

#	ARTICLE	IF	CITATIONS
37	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020, 382, 1208-1218.	27.0	207
38	Impact of diabetes mellitus on immature platelet fraction and its association with coronary artery disease. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3290.	4.0	2
39	Left Ventricular End-Systolic Dimension and Outcome in Patients With Heart Failure Undergoing Percutaneous MitraClip Valve Repair for Secondary Mitral Regurgitation. <i>American Journal of Cardiology</i> , 2020, 126, 56-65.	1.6	12
40	Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysis—Multicenter SVG PCI PROTECTA Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1198.	2.4	3
41	Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-12.	2.5	5
42	Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. <i>Cardiovascular Diabetology</i> , 2020, 19, 215.	6.8	30
43	Coronary plaque redistribution after stent implantation is determined by lipid composition: A NIRS-IVUS analysis. <i>Cardiology Journal</i> , 2020, 27, 238-245.	1.2	2
44	Beta-blocker effect on ST-segment: a prespecified analysis of the EARLY-BAMI randomised trial. <i>Open Heart</i> , 2020, 7, .	2.3	0
45	Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 127-138.	3.0	14
46	Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. <i>Postępy W Kardiologii Interwencyjnej</i> , 2019, 15, 143-150.	0.2	5
47	1-Year Outcomes of Delayed Versus Immediate Intervention in Patients With Transient ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2272-2282.	2.9	16
48	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1-month of dual antiplatelet therapy. <i>American Heart Journal</i> , 2019, 214, 134-141.	2.7	31
49	Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. <i>Vascular Pharmacology</i> , 2019, 120, 106564.	2.1	12
50	Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 413-421.	2.1	7
51	Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials. <i>Atherosclerosis</i> , 2019, 284, 136-147.	0.8	11
52	IMMEDIATE VERSUS DELAYED REVASCLARIZATION IN PATIENTS WITH TRANSIENT ST-ELEVATION MYOCARDIAL INFARCTION: 1-YEAR FOLLOW-UP OF THE RANDOMIZED CLINICAL TRANSIENT TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1218.	2.8	0
53	Treatment of Functional Mitral Regurgitation in Heart Failure. <i>Current Cardiology Reports</i> , 2019, 21, 139.	2.9	1
54	Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment. <i>Platelets</i> , 2019, 30, 915-922.	2.3	3

#	ARTICLE	IF	CITATIONS
55	Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial. <i>European Heart Journal</i> , 2019, 40, 283-291.	2.2	38
56	Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment. <i>International Journal of Cardiology</i> , 2019, 284, 16-21.	1.7	7
57	Entrapment of dissection flap and intimal tissue cleavage during rotational atherectomy. <i>Cardiovascular Intervention and Therapeutics</i> , 2019, 34, 178-179.	2.3	0
58	Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). <i>EuroIntervention</i> , 2019, 15, e990-e998.	3.2	122
59	Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. <i>Pharmacological Research</i> , 2018, 129, 27-33.	7.1	18
60	Percutaneous Versus Surgical Revascularization for Left Main or Multivessel Coronary Artery Disease: Results From a Large-Scale Meta-Analysis in the Era of Drug-Eluting Stents. <i>Angiology</i> , 2018, 69, 812-824.	1.8	13
61	Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 102-110.	3.0	26
62	Single-staged transfemoral transcatheter aortic valve implantation and percutaneous coronary intervention with rotablation in complex coronary artery disease: a case report. <i>European Heart Journal - Case Reports</i> , 2018, 2, ty016.	0.6	0
63	Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. <i>BMJ: British Medical Journal</i> , 2018, 363, k3793.	2.3	125
64	Risks of Opioids in ST-Elevation Myocardial Infarction: A Review. <i>Drug Safety</i> , 2018, 41, 1303-1308.	3.2	4
65	One-year clinical outcome of early administration of intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary reperfusion. <i>EuroIntervention</i> , 2018, 14, 688-691.	3.2	5
66	Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial. <i>EuroIntervention</i> , 2018, 14, e1207-e1214.	3.2	14
67	Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 451-458.	5.3	34
68	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial". <i>American Heart Journal</i> , 2017, 188, 11-17.	2.7	13
69	Optical coherence tomography for strategy planning and staged optimization of spontaneous coronary artery dissection. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 939-939.	1.2	4
70	Early Detection and Treatment of the Vulnerable Coronary Plaque. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	60
71	Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2017, 244, 121-127.	1.7	52
72	Coronary artery stenoses more often overestimated in older patients. <i>International Journal of Cardiology</i> , 2017, 241, 46-49.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Factors associated with deferred lesion failure following fractional flow reserve assessment in patients with diabetes mellitus. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1077-1083.	1.7	10
74	Is ischemia the only factor predicting cardiovascular outcomes in all diabetes mellitus patients?. <i>Cardiovascular Diabetology</i> , 2017, 16, 51.	6.8	22
75	Predictive value of NT-proBNP for 30-day mortality in patients with non-ST-elevation acute coronary syndromes: a comparison with the GRACE and TIMI risk scores. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 471-476.	2.3	14
76	Combined optical coherence tomography morphologic and fractional flow reserve hemodynamic assessment of non-culprit lesions to better predict adverse event outcomes in diabetes mellitus patients: COMBINE (OCT+FFR) prospective study. Rationale and design. <i>Cardiovascular Diabetology</i> , 2016, 15, 144.	6.8	34
77	TCT-94 Impact of Thin-Cap Fibroatheromas on Unanticipated Ischemic Events in Medically Treated Patients With Diabetes Mellitus: Insights From the PROSPECT Study. <i>Journal of the American College of Cardiology</i> , 2016, 68, B38-B39.	2.8	0
78	Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2016, 15, 100.	6.8	35
79	Fractional Flow Reserve-Guided Deferred Versus Complete Revascularization in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2016, 118, 1293-1299.	1.6	17
80	Cardiogenic Shock Predicts Long-Term Mortality in Hospital Survivors of <sc>STEMI</sc> Treated With Primary Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2016, 39, 665-669.	1.8	14
81	Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents. Circulation: <i>Cardiovascular Interventions</i> , 2015, 8, .	3.9	67
82	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2111-2118.	2.8	85
83	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. <i>Lancet, The</i> , 2012, 379, 1393-1402.	13.7	854
84	Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial. <i>EuroIntervention</i> , 2012, 7, 1376-1385.	3.2	34
85	Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. <i>EuroIntervention</i> , 2012, 8, 599-606.	3.2	51
86	Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. <i>Lancet, The</i> , 2010, 375, 201-209.	13.7	641